Non-Hodgkin's Lymphoma Clinical Trial
Official title:
A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA
Verified date | May 2019 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).
Status | Completed |
Enrollment | 101 |
Est. completion date | June 2018 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Have confirmed mantle cell lymphoma diagnosis. - Have measurable disease. - Have received at least 2 prior treatment, which may include stem cell transplant. - Have adequate organ and bone marrow function. - There are other criteria--please discuss with your doctor. Exclusion Criteria: - Had any prior treatment with temsirolimus or mTOR inhibitor. - Had allogeneic stem cell transplant within last 6 months and on immunosuppressive therapy. - Has active or untreated brain or central nervous system metastases. - There are other criteria--please discuss with your doctor. |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital | Adelaide | South Australia |
Australia | Box Hill Hospital | Box Hill | Victoria |
Australia | Royal Hobart Hospital | Hobart | Tasmania |
Australia | St George Hospital | Kogarah | New South Wales |
Australia | The Alfred Hospital | Melbourne | Victoria |
Czechia | Fakultni nemocnice Kralovske Vinohrady | Praha 10 | Czech Republic |
Czechia | Fakultni nemocnice Kralovske Vinohrady | Praha 10 | |
Czechia | Vseobecna fakultni nemocnice v Praze | Praha 2 | |
France | CHU de Nancy | Vandoeuvre les Nancy | |
Germany | Klinik fuer Onkologie und Haematologie, Medizinische Klinik IV | Aachen | |
Germany | Klinikum Johannes-Gutenberg -Universitaet, III. Medizinische Klinik und Poliklinik | Mainz | |
Italy | Presidio Ferrarotto - A.O.U. - PoliclinicoVittorio Emanuele | Catania | |
Italy | Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica | Modena | |
Italy | Struttura Complessa di Ematologia, Dipartimento di Oncologia ed Ematologia- | Torino | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Severance Hospital, Yonsei University | Seoul | |
Poland | Malopolskie Centrum Medyczne S.C. | Krakow | |
Romania | Institutul Clinic Fundeni Bucuresti, Sectia II Hematologie | Bucuresti | |
Romania | Spitalul Clinic Coltea, Clinica de Hematologie | Bucuresti | |
Romania | Spitalul Universitar de Urgenta Bucuresti, Clinica de Hematologie | Bucuresti | |
Russian Federation | Republican Clinical Oncology Dispensary of the Ministry of Healthcare of Tatarstan Republic | Kazan | |
Russian Federation | GBOU VPO "First Saint-Petersburg State Medical University n.a. I.P.Pavlov" | Saint-Petersburg | |
Russian Federation | Institute of Pediatric Hematology and Transplantology R.M.Gorbacheva | Saint-Petersburg | |
Serbia | Clinical Centre of Serbia,Clinic for Hematology | Belgrade | |
Serbia | Oncology Institute of Vojvodina | Sremska Kamenica | |
United States | Veterans Affairs New Jersey Healthcare System-Hematology/Oncology Section (111) | East Orange | New Jersey |
United States | Mercy Research Institute | Miami | Florida |
United States | Mercy Clinic Oklahoma Communities dba Mercy Clinic Oncology/Hematology-McAuley | Oklahoma City | Oklahoma |
United States | Mercy Hospital Oklahoma City-Oncology Infusion | Oklahoma City | Oklahoma |
United States | Amy Shen, RPh | Seattle | Washington |
United States | VA Puget Sound Health Care System | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Australia, Czechia, France, Germany, Italy, Korea, Republic of, Poland, Romania, Russian Federation, Serbia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Independently Assessed Progression-free Survival (PFS) | PFS is defined as the time from randomization to first documentation of disease progression by the independent assessor or to death due to any cause, whichever occurred first. PFS = (earliest date of progression or death due to any cause- randomization date+1)/30.4. PFS assessment was done using EMA guidelines for sensitivity analysis censoring. Participants who were alive and progression-free at the time of analysis were censored on the date of last assessment; participants without adequate baseline assessment or without post-baseline assessments were censored on the randomization date; participants who died or progressed after 2 or more missed visits were censored on the date of last tumor assessment prior to the missing visit; and participants who started new anti-cancer therapy prior to death or progression were censored on the date of last tumor assessment prior to the start of anti-tumor treatment. |
From randomization date to the date of first documentation of progression or death (average follow up done for 15 months) | |
Secondary | Overall Survival (OS) | OS is defined as the time from the date of randomization to the date of death due to any cause. | From randomization date until death due to any cause (average follow up done for 56.1 months) | |
Secondary | Independent Assessment - Objective Response Rate (ORR = CR + PR) | ORR is defined as the percentage of participants with confirmed CR or PR according to the Cheson Criteria relative to all randomized Participants. Tumor responses were determined using information from objective measurements from computed tomography information including B-symptom evaluation, physical examination, ECOG performance status, assessment of liver and spleen, laboratory assessments such as bone marrow biopsies and/or aspirates, biochemical markers of disease activity and hematology results. Participants who did not have on-study radiographic tumor re-evaluation or who died, progressed or dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the (CT) scans, as well as clinical assessment of ORR. |
From randomization date until end of treatment (average follow up done for 15 months) | |
Secondary | Investigator's Assessment ORR (ORR = CR + PR) | ORR is defined as the percentage of participants with confirmed CR or PR according to the Cheson Criteria relative to all randomized Participants. Tumor responses were determined using information from objective measurements from computed tomography information including B-symptom evaluation, physical examination, ECOG performance status, assessment of liver and spleen, laboratory assessments such as bone marrow biopsies and/or aspirates, biochemical markers of disease activity and hematology results. Participants who did not have on-study radiographic tumor re-evaluation or who died, progressed or dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the (CT) scans, as well as clinical assessment of ORR. |
From randomization date until end of treatment (average follow up done for 15 months) | |
Secondary | Investigator Assessed PFS | PFS is defined as the time from randomization to first documentation of disease progression by the independent assessor or to death due to any cause, whichever occurred first. PFS = (earliest date of progression or death due to any cause- randomization date+1)/30.4. PFS assessment was done using EMA guidelines for sensitivity analysis censoring. Participants who were alive and progression-free at the time of analysis were censored on the date of last assessment; participants without adequate baseline assessment or without post-baseline assessments were censored on the randomization date; participants who died or progressed after 2 or more missed visits were censored on the date of last tumor assessment prior to the missing visit; and participants who started new anti-cancer therapy prior to death or progression were censored on the date of last tumor assessment prior to the start of anti-tumor treatment. |
From randomization date to the date of first documentation of progression or death (average follow up done for 15 months) | |
Secondary | Percentage of Participants With Treatment-Emergent Infection- Related Adverse Events (AEs) With Grade 2 or Higher as Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) | An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Treatment emergent adverse event=as an event that emerged during treatment period that was absent before treatment, or worsened during treatment period relative to pretreatment state. Treatment-emergent infection-related AEs included events: pneumonia, bronchitis, infection, herpes simplex, oral candidiasis and sepsis. Grading by NCI CTCAE Version 3.0.: Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening; urgent intervention indicated; Grade 5= death. | From screening up to a maximum of 57.1 months | |
Secondary | Percentage of Participants With Treatment-Emergent Bleeding-Related AEs With Grade 2 or Higher as Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) | An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Treatment emergent adverse event=as an event that emerged during treatment period that was absent before treatment, or worsened during treatment period relative to pretreatment state. Treatment-emergent bleeding related AEs included events: epistaxis and ecchymosis. AE were assessed according to maximum severity grading based on NCI CTCAE Version 4.03.Grade 1=mild; Grade 2=moderate; within normal limits. Grade 3=severe or medically significant but not immediately life-threatening; Grade 4=life-threatening or disabling; urgent intervention indicated; Grade 5=death. | From screening up to a maximum of 57.1 months | |
Secondary | Quantify the Potential Effect of TEMSR on AUC and Cmax | Potential TEMSR effects were investigated by calculating the ratio of AUCs with and without concomitant TEMSR from the model-estimated effect of TEMSR on apparent clearance (CL/F) values and using individual ratios of observed Cmax values with and without concomitant temsirolimus, for both parent and metabolite. The AUC mean ratio was calculated as 1 / mean shift on apparent clearance from TEMSR, and the 90% CI of the AUC ratios was calculated as 1 / 90% CI of the shift on apparent clearance from TEMSR. AUC: Area under plasma concentration-time curve from time zero to infinity Cmax: Characterization of maximum observed plasma concentration |
From one week predose (Day -7, -4hr, -8hr, -48hr) upto 2 weeks post dose (4hr, 8hr, 48hr and Day 8) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Completed |
NCT04152148 -
A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients
|
Phase 1 | |
Recruiting |
NCT05191225 -
Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study
|
Phase 4 | |
Recruiting |
NCT05096234 -
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
|
Phase 2 | |
Recruiting |
NCT05623982 -
Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03664635 -
MB-CART20.1 Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
Terminated |
NCT01699581 -
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT01763398 -
Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study
|
N/A | |
Completed |
NCT01205503 -
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
|
Phase 2 | |
Completed |
NCT00969462 -
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
|
Phase 4 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00659425 -
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Withdrawn |
NCT00577161 -
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
|
Phase 3 | |
Completed |
NCT00533728 -
Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT00608907 -
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
|
Phase 1 | |
Terminated |
NCT00475332 -
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
|
Phase 2 | |
Completed |
NCT00581646 -
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
|
N/A | |
Completed |
NCT00430352 -
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
|
Phase 4 |